N-(3-氯苯基)-N-甲基-3-[[3,5-二甲基-4-[(4-甲基哌嗪-1-基)羰基-1H-吡咯-2-基]亚甲基]-2-氧代-2,3-二氢-1H-吲哚-5-磺酰胺结构式
|
常用名 | N-(3-氯苯基)-N-甲基-3-[[3,5-二甲基-4-[(4-甲基哌嗪-1-基)羰基-1H-吡咯-2-基]亚甲基]-2-氧代-2,3-二氢-1H-吲哚-5-磺酰胺 | 英文名 | SU11274 |
|---|---|---|---|---|
| CAS号 | 658084-23-2 | 分子量 | 568.087 | |
| 密度 | 1.4±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C28H30ClN5O4S | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells.
Cancer Biol. Ther. 16(1) , 170-5, (2015) Vestibular schwannoma (VS), the fourth most common intracranial tumor, arises from the Schwann cells of the vestibular nerve. Although several pathways have been independently implicated in VS pathobiology, interactions among these pathways have not been expl... |
|
|
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
PLoS ONE 8(3) , e59708, (2013) Epidermal growth factor receptor (EGFR) and c-MET receptors are expressed on many non-small cell lung cancer (NSCLC) cells. Current single agent therapeutic targeting of a mutant EGFR has a high efficacy in the clinic, but is not curative. Here, we investigat... |
|
|
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Cancer Res. 65 , 1479-1488, (2005) Non-small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence that c-Met is overexpressed, activated, and sometimes mutate... |
|
|
c-Met inhibitors.
Infect. Agents Cancer 8(1) , 13, (2013) c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzym... |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved
